Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Phasebio Pharmaceuticals Inc (PHAS)

Phasebio Pharmaceuticals Inc (PHAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Phasebio Pharmaceuticals Inc 1 Great Valley Parkway Suite 30 Malvern PA 19355 USA

www.phasebio.com P: 610-981-6500

Description:

PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States.

Key Statistics

Overview:

Market Capitalization, $K 3,495
Enterprise Value, $K -31,535
Shares Outstanding, K 49,858
Annual Sales, $ 10,830 K
Annual Net Income, $ -131,070 K
Last Quarter Sales, $ 210 K
Last Quarter Net Income, $ -16,670 K
60-Month Beta 2.57
% of Insider Shareholders 9.90%
% of Institutional Shareholders 49.02%
Float, K 44,922
% Float 90.10%
Short Volume Ratio 0.36

Growth:

1-Year Return -98.27%
3-Year Return -98.23%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.34 on 08/12/22
Latest Earnings Date 11/09/22
Earnings Per Share ttm -2.13
EPS Growth vs. Prev Qtr -47.83%
EPS Growth vs. Prev Year 43.33%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PHAS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -206.61%
Profit Margin % -1,210.25%
Debt/Equity 0.00
Price/Sales 0.44
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -2.41
Interest Coverage -135.28
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar